NASDAQ

Agenus Inc. (AGEN)

563 Thanks from members

Agenus Inc. (AGEN) presents a classic biotech crossroads, balancing high-stakes potential from its lead immuno-oncology combination BOT+BAL against persistent balance sheet pressures and going concern warnings despite recent capital raises.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →